Drug Profile

BGM 0504

Alternative Names: BGM-0504

Latest Information Update: 27 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BrightGene Bio-medical technology
Class Antihyperglycaemics; Obesity therapies; Peptides
Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Obesity; Type 2 diabetes mellitus

Most Recent Events

24 Jun 2025 Efficacy and adverse event data from a phase II trial in Obesity released by BrightGene Bio-medical technology
24 Jun 2025 Efficacy and adverse event data from a phase II trial in Type 2 diabetes mellitus released by BrightGene Bio-medical technology
24 Jun 2025 BrightGene completes a phase I trial in Obesity in USA (SC) (NCT06714955)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com